MedTech News

Silk sponges instead of animal testing: How a 3D cell culture system could advance cancer diagnostics
A consortium of Austrian research groups from the University of Vienna, MedUni Vienna and Technikum Wien, together with company partner DOC Medikus GmbH, has developed an innovative bioanalytical test system for radiopharmaceutical drug candidates for cancer diagnosis and therapy.

Breakthrough Device Designation for ReFlow® External Ventricular Drains (EVD)
SCOTTSDALE, Ariz., March 20, 2025 /PRNewswire/ — Anuncia Medical, Inc. (“Anuncia”), a pioneering company in CSF management and neurocritical care, has received Breakthrough Device Designation from the FDA for its ReFlow® EVD, an innovative solution for external ventricular drains (EVDs) used to manage brain swelling and elevated intracranial pressure.

Sibel Health raises $30M, adds another FDA clearance
Sibel Health announced today that it closed a $30 million equity financing and earned its seventh FDA 510(k) clearance.

GE HealthCare launches AI-driven breast cancer detection tech
GE HealthCare (Nasdaq: GEHC) announced today that it launched its Invenia automated breast ultrasound (ABUS) premium offering.

Painless technique can estimate glucose concentrations in solution and tissue via sound waves
Blood glucose is usually measured using invasive methods involving pricking small needles into the skin. But people suffering from diabetes have to test their glucose levels many times a day. This repeated use of needles is inconvenient and can increase the risk of potential infections.

Powerful new MRI scans enable life-changing surgery in first for adults with epilepsy
A new technique has enabled ultra-powerful magnetic resonance imaging (MRI) scanners to identify tiny differences in patients’ brains that cause treatment-resistant epilepsy. In the first study to use this approach, it has allowed doctors at Addenbrooke’s Hospital, Cambridge, to offer the patients surgery to cure their condition.

BD Announces Milestone in Clinical Trial for Use of Bioabsorbable GalaFLEX LITE™ Scaffold in Breast Implant Revision Surgery
FRANKLIN LAKES, N.J., March 20, 2025 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the first patient treated in an Investigational Device Exemption (IDE) clinical trial intended to advance BD’s efforts to achieve Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for the use of GalaFLEX LITE™ Scaffold in decreasing capsular contracture (CC) recurrence during breast revision surgery.

Medtronic reports first real-world data on smart insulin pen system
Medtronic (NYSE:MDT) today announced real-world data supporting the use of its smart insulin pen and CGM sensor combination.